Precision Peptide Co · Needle-Free Peptides

The Precision Peptide Company's Needle-Free First Strategy Already in Place as @HHSgov Draft Policy Recognizes Non-Injectable Routes for Leading Peptides The Precision Peptide Company Inc. today comments on the "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", published by the U.S. Department of Health and Human Services in the Federal Register on Oct 30, 2026 under Docket No. HHS-OASH-2026-0496, and its potential relevance to the Company's U.S. prescription platform and needle-free delivery strategy. Body Protection Compound-157, the peptide the Company takes its ticker symbol from, heads the Policy's list... CSE: $BPC | OTC: PNGAF

Some people watch the needle go in. Some people stare at a ceiling tile and count to 10. If you’re a ceiling tile person, most of our range was made with you in mind.

The Precision Peptide Company Quadruples U.S. Telehealth Formulary to 16 Prescription Therapies Across Seven Therapy Areas The Precision Peptide Company Inc. today announced that it has quadrupled its U.S. telehealth formulary to 16 prescription therapies across seven therapy areas, less than four months after launching nationwide telehealth access. The expansion builds on the Company's 503A sterile compounding agreement (see news release dated June 2, 2026), its prescription and telehealth infrastructure partnership (see news release dated June 9, 2026) and its consumer-facing telehealth website (see news release dated July 7, 2026). CSE: $BPC | OTC: PNGAF

The Precision Peptide Company Highlights 30 Years of Peptide Science Behind Its Product Platform. The Precision Peptide Company today highlights the scientific leadership and development approach behind its product platform, led by Co-Founder and Chief Scientific Officer Justin Kirkland. Mr. Kirkland is a chemist whose career spans more than 30 years of making peptides. His experience covers natural products, small molecules, peptide synthesis, analytical chemistry and drug formulation for improved bioavailability. He holds a BS in Agronomy and an MS in Biology. His background shapes how the Company develops every product. The Company's process is built around three questions: how the peptide is made, how its purity is verified, and how it is delivered. CSE: $BPC | OTC: PNGAF

The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line The Precision Peptide Company Inc. today announced that it has secured exclusive manufacturing rights from its U.S. manufacturer to all four of its patch formulations: BPC-157, Thymosin Alpha-1 (TA1), Tirzepatide and GLP transdermal patches. Each patch will be produced solely for The Precision Peptide Company. Each product follows a similar production cycle: formulation, formal U.S. testing, a commercial production order and release. The BPC-157 patch has completed it, TA1 is on the final step, and the Company intends to move Tirzepatide and GLP+ along the same route. CSE:$BPC | OTC:PNGAF

The Precision Peptide Company Begins Development of GLP3 Patch, Its Fourth Needle-Free Peptide The Precision Peptide Company today announced that it has begun development of a GLP3 transdermal patch in the United States, the fourth product in its needle-free peptide patch line and its second in the metabolic and weight-management category. GLP3 enters a product line that already includes one patch on sale, one in production and one in development, and it will follow the same process each of them has taken. Pratap Sandhu, CEO of The Precision Peptide Company, commented: "Tirzepatide was our first step into metabolic and weight management. GLP3 is the second. Both are being built on the platform that took BPC-157 from formulation through independent U.S. testing to a product on sale, and that has 20,000 TA1 patches in production today. We are not changing the method with each new peptide; we are repeating it. Formulate in the United States, test in the United States, produce in the United States, then release. GLP3 enters that cycle today, and it is designed for consumers who prefer not to use a syringe." CSE: $BPC | OTC:PNGAF

The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing. The patch was first announced as under development on August 19, 2026. It is being designed to deliver tirzepatide, the active ingredient in existing injectable tirzepatide products, without a needle and without refrigeration. Testing is being conducted entirely in the United States through the Company's domestic product-development infrastructure. Subject to the results, the Company intends to advance the product toward commercial production. CSE: $BPC | OTC: PNGAF